Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging

Trial Profile

Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Fresolimumab (Primary)
  • Indications Glioma
  • Focus Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Nov 2011 Trial lead investigator identified as reported by ClinicalTrials.gov.
    • 17 Nov 2011 Company (Genzyme Corporation) added as trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top